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Therapy of acute myocardial  
infarction in Switzerland –  
the AMIS Plus Registry
AMIS Plus, the Swiss national registry of acute myocardial infarction (MI), foun-
ded by the Swiss Societies of Internal Medicine, Cardiology and Intensive Care 
Medicine, supports robust quality improvement efforts designed to encourage 
evidence-based acute cardiac care and ultimately improve patient outcome. Since 
1997, data of patients hospitalized in 81 Swiss hospitals with acute coronary  
syndromes are collected, and in June 2012, the 40’000th patient was enrolled. 
AMIS Plus is the largest health care 
registry in Switzerland. Essentially, it 
is a tool for monitoring and under-
standing the use and practicability of 
knowledge gained from randomized 
trials, how these transfer into real-
world clinical situations and locate 
where there is room for optimization. 
All Swiss hospitals treating MI are 
eligible to take part. Participating cen-
ters, ranging from community care ins-
titutions to large tertiary care facilities, 
provide blinded data for each patient 
through a standardized internet- or 
paper-based questionnaire. These are 
checked for plausibility and consisten-
cy by the AMIS Plus Data Center in 
the Institute of Social and Preventive 
Medicine at the University of Zurich. 
Data quality is of utmost priority and 
external random monitoring is con-
ducted annually. The registry was ap-
proved by the Supra-Regional Ethics 
Committee for Clinical Studies, the 
Swiss Board for Data Security and the 
cantonal ethics commissions.1
Throughout the years, the question-
naire has been regularly revised and 
improved in order to take into account 
advances in patient treatment. In or-
der to evaluate mid-term outcome, 
patients enrolled in the AMIS Plus 
registry who gave their formal signed 
consent are contacted 3 months and 
1 year after the event. Approximately 
40% of the patients were asked and 
interviews were successfully carried 
out with over 90% of these patients. 
The AMIS Plus online reporting sys-
tem - only available to the authorized 
person in charge of AMIS Plus in each 
hospital - allows hospital benchmar-
king using current AMIS Plus hospital 
data against the AMIS Plus data of all 
other hospitals or against hospitals of 
the same size. 
The selected analyses of the entire 
AMIS Plus patient population can be 
depicted according to admission year, 
age categories, sex or diagnosis. This 
way, the knowledge gained (“learn 
from the best and improve”) enab-
les a quick translation into everyday 
practice.
During the last 15 years, in-hospital 
mortality has drastically reduced as 
has hospital stay. The time needed for 
work-up in hospital has been impor-
tantly reduced and the large burden of 
therapies switched from lytic therapies 
to percutaneous mechanical therapy.2
All information pertaining to this 
project can be found at www.amis-
plus.ch.
Using the AMIS Plus data of 6777 
patients from the last 3 years (2010-
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2012) we show how MI patients are 
currently treated in Switzerland. 
MI patients 
The baseline characteristics of the pa-
tients with ST-elevation MI (STEMI) 
and non-STEMI (NSTEMI) are shown 
in table 1. 
How are MI patients treated in Switzer-
land today?
Time between symptom onset and first 
medical contact is still too long. It took 
more than 100 minutes before a pa-
tient with STEMI contacted a doctor 
and approximately 180 minutes for 
NSTEMI patients. Then another hour 
passed before the STEMI patients arri-
ved at hospital. Less than a quarter of 
MI patients arrived in hospital within 6 
hours. In contrast to randomized clini-
cal trials, AMIS Plus data have shown 
that around 2% of all patients with MI 
are palliatively treated receiving only 
aspirin and symptomatic therapy due 
to their general status, the severity of 
comorbidities, critical illness or deni-
al of specific, especially interventional 
therapy. 
Almost 25% of NSTEMI patients and 
11% of STEMI patients were treated 
conservatively. Although thromboly-
sis was the reperfusion option in the 
1990s, this is no longer the case. Less 
than 1% of the patients presenting with 
STEMI in this study were treated with 
thrombolysis. The majority of patients 
- over 86% - underwent a percutane-
ous coronary intervention (PCI), which 
was the primary strategy for 80% of 
patients. Time between admission and 
start of intervention - “door-to-balloon 
time” - is short in Switzerland with a 
median of 55min. This indicator of 
treatment quality is even more impor-
tant if we take into consideration that 
around 27% of patients were initially 
admitted to smaller hospitals before 
being transferred for intervention. 
From the AMIS patients who under-
went PCI, 95% received one or more 
stents; 25% of the patients received ba-
re-metal stents and 75% of the patients 
received drug eluting stents.
Early drug therapy is depicted in 
Figure 1. 
Anticoagulant options included un-
fractionated heparin or low molecu-
lar weight heparin and was given to 
almost all AMI patients. In addition, 
a variety of anticoagulant drugs have 
undergone clinical evaluation in ran-
domized trials over the past decade, 
such as fondaparinux, bivalirudin and 
an inhibitor of factor Xa - rivaroxa-
ban. These anticoagulants are slowly 
moving into the real world population 
with fondaparinux being used in over 
2%, bivalirudin in 1.5% and rivaro-
xaban in around 0.5% of MI patients. 
sTemi nsTemi
age in years (mean±sd) 65±13 67±13
female (%) 26 27
Coronary artery disease (%) 27 41
Cerebrovascular disease (%) 5 7
Heart failure (%) 3 3
diabetes (%) 18 23
renal disease (%) 7 9
Cancer (%) 6 6
Hypertension (%) 58 68
dyslipidemia (%) 51 59
Current smoker (%) 42 35
obese (Bmi>30) (%) 22 23
resuscitation prior admission (%) 7 3
Killip classes >2 (%) 10 6
sTemi: ST-elevation myocardial infarction                              nsTemi: Non-ST-elevation myocardial infarction
Table 1: Baseline characteristics of the patients presenting with acute myocardial infarction
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Fig. 1: Early drug therapy in the patients presenting with acute myocardial infarction
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GPIIb/IIIa inhibitor was rarely prescri-
bed compared to a few years ago. The 
new ESC Guidelines3 recommend an 
ADP-receptor blocker (P2Y12 blo-
cker) in addition to aspirin for patients 
presenting with STEMI. The most fre-
quently used P2Y12 blockers are cur-
rently clopidogrel (67%), followed by 
prasugrel (27%) and ticagrelor (8%).
Angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers 
are well established and were given to 
patients with impaired ejection frac-
tion or heart failure in the early pha-
se. Beta blocker therapy is beneficial 
to AMI patients4 and was provided to 
half the AMIS patients. Many clinical 
trials have equivocally demonstrated 
the benefit of early and intensive sta-
tin therapy.5 This is well implemented 
in daily clinical practice in Switzerland 
with over 70% of all AMI patients re-
ceiving statins. 
Of the discharged AMI patients, the 
majority received evidence-based me-
dication, but only one third went di-
rectly to rehabilitation. 
In the last decade, the great impro-
vement in treatment of AMI patients 
has led to a halving of the in-hospi-
tal mortality rate which is currently 
around 5%.  
Thanks to the excellent work carried 
out by the numerous hospitals and the 
Data Center, the AMIS Plus Project 
helps all players ensure that patients 
with MI in Switzerland are provided 
with the best possible treatment.  n
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